Outcomes of Eltrombopag Treatment and Development of Iron Deficiency in Children with Immune Thrombocytopenia in Turkey

Basit Öğe Kaydı
dc.contributor.authorYozgat, Ayca Koca
dc.contributor.authorLeblebisatan, Goksel
dc.contributor.authorAkbayram, Sinan
dc.contributor.authorOzel, Simge Cinar
dc.contributor.authorKarakas, Zeynep
dc.contributor.authorErduran, Erol
dc.contributor.authorYilmaz, Sebnem
dc.date.accessioned2024-02-23T14:38:16Z
dc.date.available2024-02-23T14:38:16Z
dc.date.issued2020
dc.departmentNEÜen_US
dc.description.abstractObjective: Immune thrombocytopenia (ITP) is a rare autoimmune disease and hematologic disorder characterized by reduced platelet counts that can result in significant symptoms, such as bleeding, bruising, epistaxis, or petechiae. The thrombopoietin receptor agonist eltrombopag (EPAG) is a second-line agent used to treat chronic ITP purpura in adults and children. Materials and Methods: The present retrospective study evaluated the efficacy, safety, and side effects of EPAG treatment in pediatric patients with acute refractory and chronic immune thrombocytopenia, particularly focusing on iron-deficiency anemia. Results: The diagnosis was chronic ITP in 89 patients and acute refractory ITP in 16 patients. The mean age of patients was 9.5 +/- 4.5 years (minimum-maximum: 1.2-18 years) at the beginning of EPAG treatment. The overall response rate was 74.3% (n=78). The mean time for platelet count of >= 50x109/L was 11.6 +/- 8 weeks (range: 1-34 weeks). The treatment was stopped for 27 patients (25.7%) at an average of 6.8 +/- 9 months (range: 1-38 months). The reason for discontinuation was lack of response in 18 patients, nonadherence in 4 patients, and hepatotoxicity in 2 patients. Response to treatment continued for an average of 4 months after cessation of EPAG in 3 patients. Conclusion: Results of the current study imply that EPAG is an effective therapeutic option in pediatric patients with acute refractory and chronic ITP. However, patients must be closely monitored for response and side effects during treatment, and especially for iron deficiency.en_US
dc.identifier.doi10.4274/tjh.galenos.2020.2019.0380
dc.identifier.endpage144en_US
dc.identifier.issn1300-7777
dc.identifier.issn1308-5263
dc.identifier.issue3en_US
dc.identifier.pmid32181630en_US
dc.identifier.scopus2-s2.0-85090080214en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage139en_US
dc.identifier.urihttps://doi.org/10.4274/tjh.galenos.2020.2019.0380
dc.identifier.urihttps://hdl.handle.net/20.500.12452/16447
dc.identifier.volume37en_US
dc.identifier.wosWOS:000564138800001en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherGalenos Yayinciliken_US
dc.relation.ispartofTurkish Journal Of Hematologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectImmune Thrombocytopeniaen_US
dc.subjectEltrombopagen_US
dc.subjectIron Deficiencyen_US
dc.titleOutcomes of Eltrombopag Treatment and Development of Iron Deficiency in Children with Immune Thrombocytopenia in Turkeyen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu